LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
Posted on 7466 LEO Pharma A/S – a global leader in medical dermatology – announced today that the first patient has been screened in the first head-to-head clinical trial to evaluate brodalumab (marketed in the European Union as Kyntheum ®) compared with guselkumab (marketed globally as Tremfya ®) in adult patients with moderate-to-severe plaque psoriasis who have an inadequate response to ustekinumab (marketed globally as Stelara ®) treatment. Per Sproegel (Photo: Business Wire) The COBRA (COmparing BRodalumab And guselkuma...
Source: financialbuzz.com